CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

This study examines the safety, tolerability and preliminary efficacy of anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.

Trial Details

NCT ID
NCT06445803
Phase
PHASE1
Sponsor
Rong Tao
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）
Locations (sample)
  • Nanchang, Jiangxi, China|28.68396,115.85306
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Male or female,≥18 years old;
  • Histologically confirmed diagnosis of B-ALL or B-NHL(meeting one of the following conditions):
  • Second or greater relapse (CD20 regimens must be included) OR
  • Refractory to first-line chemotherapy or relapse within 1 year OR

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →